FDA rejects Hengrui, Elevar’s PD-1 liver cancer combo for a 3rd time

The third time is not the charm for Hengrui Pharma and Elevar Therapeutics’ star-crossed combination of camrelizumab and rivoceranib at the FDA. | The third time is not the charm for Hengrui Pharma and Elevar Therapeutics. The pair’s star-crossed cancer drug combination of camrelizumab and rivoceranib has been rejected by the FDA for the third time.